Regeneron Pharmaceuticals (NASDAQ:REGN) Posts Quarterly Earnings Results, Beats Expectations By $0.86 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86, RTT News reports. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $11.86 EPS.

Regeneron Pharmaceuticals Trading Up 1.0 %

Shares of NASDAQ:REGN traded up $7.01 during mid-day trading on Thursday, reaching $723.73. 216,725 shares of the company’s stock were exchanged, compared to its average volume of 918,547. The business’s fifty day moving average price is $717.27 and its 200-day moving average price is $914.93. Regeneron Pharmaceuticals has a twelve month low of $642.00 and a twelve month high of $1,211.20. The firm has a market capitalization of $79.53 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 1.60 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Evercore ISI cut their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Citigroup decreased their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.